Heron Therapeutics’ Product HTX-011: Helping in the War Against Opioids. Why Regeneron Could Fiercely Rebound

What Do We Make of the Following Good News?
Will HTX-011 Help in the War Against Opioids? 

Heron Therapeutics (HRTX), a commercial-stage biotechnology company announced positive results from its completed Phase 3 studies of the investigational agent HTX-011 in people undergoing bunionectomy and hernia repair. HTX-011 is described as the first and only long-acting local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and opioid use compared to standard of care product bupivacaine solution for postoperative pain control, through . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.